A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients.

ABSTRACT: Patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) are generally older and have more comorbidities. Therefore, identifying personalized treatment options for each patient early and accurately is essential. To address this, we developed a computational biology modeling (CBM) and digital drug simulation platform that relies on somatic gene mutations and gene CNVs found in malignant cells of individual patients. Drug treatment simulations based on unique patient-specific disease networks were used to generate treatment predictions. To evaluate the accuracy of the genomics-informed computational platform, we conducted a pilot prospective clinical study (NCT02435550) enrolling confirmed MDS and AML patients. Blinded to the empirically prescribed treatment regimen for

SUBMITTER: Drusbosky LM 

PROVIDER: S-EPMC6595252 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature